Targeting alpha toxin and ClfA with a multimechanistic monoclonal- antibody-based approach for prophylaxis of serious Staphylococcus aureus disease

mBio

Volumn 7, Issue 3, 2016, Pages

  Tkaczyk, C ^a   Hamilton, M M ^a   Sadowska, A ^a   Shi, Y ^a   Chang, C S ^a,c   Chowdhury, P ^a   Buonapane, R ^a,d   Xiao, X ^a   Warrener, P ^a   Mediavilla, J ^b   Kreiswirth, B ^b   Suzich, J ^a   Stover, C K ^a   Sellman, B R ^a  

^a MEDIMMUNE   (United States)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^c PFIZER INC   (United States)

^d Adimab LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BINDING PROTEIN; CLUMPING FACTOR A; FIBRINOGEN; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 11H10; MONOCLONAL ANTIBODY MEDI4893; STAPHYLOCOCCUS ALPHA TOXIN; UNCLASSIFIED DRUG; VIRULENCE FACTOR; BACTERIAL TOXIN; BACTERIUM ANTIBODY; CLFA PROTEIN, STAPHYLOCOCCUS AUREUS; COAGULASE; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIGEN ANTIBODY REACTION; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; COMBINATION DRUG THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SCREENING; DRUG TARGETING; FEMALE; HUMAN; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; LOW DRUG DOSE; MONOTHERAPY; MOUSE; NONHUMAN; NORMAL HUMAN; OPSONIZATION; PASSIVE IMMUNIZATION; PLASMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; SKIN NECROSIS; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCAL PNEUMONIA; STAPHYLOCOCCAL SKIN INFECTION; STAPHYLOCOCCUS INFECTION; SURVIVAL; ANIMAL; BACTERIAL LOAD; BLOOD; DISEASE MODEL; HL-60 CELL LINE; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; PHAGOCYTOSIS; PROCEDURES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BACTERIAL LOAD; BACTERIAL TOXINS; COAGULASE; DISEASE MODELS, ANIMAL; HL-60 CELLS; HUMANS; IMMUNIZATION, PASSIVE; MICE; PHAGOCYTOSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VIRULENCE FACTORS;

EID: 84979085352     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00528-16     Document Type: Article

References (70)

1. Laupland KB, Lyytikäinen O, Søgaard M, Kennedy KJ, Knudsen JD, Ostergaard C, Galbraith JC, Valiquette L, Jacobsson G, Collignon P, Schønheyder HC, International Bacteremia Surveillance Collaborative. 2013. The changing epidemiology of Staphylococcus aureus bloodstream infection: a multinational population-based surveillance study. Clin Microbiol Infect 19: 465-471. http://dx.doi.org/10.1111/j.1469-0691.2012.03903.x.
2. DiGiandomenico A, Sellman BR. 2015. Antibacterial monoclonal antibodies: the next generation? Curr Opin Microbiol 27: 78-85. http:// dx.doi.org/10.1016/j.mib.2015.07.014.
3. Morrison C. 2015. Antibacterial antibodies gain traction. Nat Rev Drug Discov 14: 737-738. http://dx.doi.org/10.1038/nrd4770.
4. Bagnoli F, Fontana MR, Soldaini E, Mishra RP, Fiaschi L, Cartocci E, Nardi-Dei V, Ruggiero P, Nosari S, De Falco MG, Lofano G, Marchi S, Galletti B, Mariotti P, Bacconi M, Torre A, Maccari S, Scarselli M, Rinaudo CD, Inoshima N, Savino S, Mori E, Rossi-Paccani S, Baudner B, Pallaoro M, Swennen E, Petracca R, Brettoni C, Liberatori S, Norais N, Monaci E, Bubeck Wardenburg J, Schneewind O, O’Hagan DT, Valiante NM, Bensi G, Bertholet S, De Gregorio E, Rappuoli R, Grandi G. 2015. Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus. Proc Natl Acad Sci U S A 112: 3680-3685. http://dx.doi.org/10.1073/ pnas.1424924112.
5. Stranger-Jones YK, Bae T, Schneewind O. 2006. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci U S A 103: 16942-16947. http://dx.doi.org/10.1073/pnas.0606863103.
6. Bubeck Wardenburg J, Schneewind O. 2008. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 205: 287-294. http:// dx.doi.org/10.1084/jem.20072208.
7. Inoshima N, Wang Y, Bubeck Wardenburg J. 2012. Genetic requirement for ADAM10 in severe Staphylococcus aureus skin infection. J Invest Dermatol 132: 1513-1516. http://dx.doi.org/10.1038/jid.2011.462 http:// dx.doi.org/10.1038/jid.2011.462.
8. Foletti D, Strop P, Shaughnessy L, Hasa-Moreno A, Casas MG, Russell M, Bee C, Wu S, Pham A, Zeng Z, Pons J, Rajpal A, Shelton D. 2013. Mechanism of action and in vivo efficacy of a human-derived antibody against Staphylococcus aureus alpha-hemolysin. J Mol Biol 425: 1641-1654 http://dx.doi.org/10.1016/j.jmb.2013.02.008.
9. Hua L, Hilliard JJ, Shi Y, Tkaczyk C, Cheng LI, Yu X, Datta V, Ren S, Feng H, Zinsou R, Keller A, O’Day T, Du Q, Cheng L, Damschroder M, Robbie G, Suzich J, Stover CK, Sellman BR. 2014. Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia. Antimicrob Agents Chemother 58: 1108-1117. http://dx.doi.org/10.1128/AAC.02190-13.
10. Tkaczyk C, Hua L, Varkey R, Shi Y, Dettinger L, Woods R, Barnes A, MacGill RS, Wilson S, Chowdhury P, Stover CK, Sellman BR. 2012. Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency. Clin Vaccine Immunol 19: 377-385. http:// dx.doi.org/10.1128/CVI.05589-11.
11. Ragle BE, Bubeck Wardenburg J. 2009. Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infect Immun 77: 2712-2718. http://dx.doi.org/10.1128/ IAI.00115-09.
12. Menzies BE, Kernodle DS. 1996. Passive immunization with antiserum to a nontoxic alpha-toxin mutant from Staphylococcus aureus is protective in a murine model. Infect Immun 64: 1839-1841.
13. Adhikari RP, Karauzum H, Sarwar J, Abaandou L, Mahmoudieh M, Boroun AR, Vu H, Nguyen T, Devi VS, Shulenin S, Warfield KL, Aman MJ. 2012. Novel structurally designed vaccine for S. aureus alphahemolysin: protection against bacteremia and pneumonia. PLoS One 7: e38567. http://dx.doi.org/10.1371/journal.pone.0038567.
14. Powers ME, Kim HK, Wang Y, Bubeck Wardenburg J. 2012. ADAM10 mediates vascular injury induced by Staphylococcus aureus alphahemolysin. J Infect Dis 206: 352-356. http://dx.doi.org/10.1093/infdis/ jis192.
15. Wilke GA, Bubeck Wardenburg J. 2010. Role of a disintegrin and metalloprotease 10 in Staphylococcus aureus alpha-hemolysin-mediated cellular injury. Proc Natl Acad SciUS A 107: 13473-13478. http://dx.doi.org/10.1073/pnas.1001815107.
16. Becker RE, Berube BJ, Sampedro GR, Dedent AC, Bubeck Wardenburg J. 2014. Tissue-specific patterning of host innate immune responses by Staphylococcus aureus _-toxin. J Innate Immun 6: 619-631. http:// dx.doi.org/10.1159/000360006.
17. Powers ME, Becker RE, Sailer A, Turner JR, Bubeck Wardenburg J. 2015. Synergistic action of Staphylococcus aureus alpha-toxin on platelets and myeloid lineage cells contributes to lethal sepsis. Cell Host Microbe 17: 775-787. http://dx.doi.org/10.1016/j.chom.2015.05.011.
18. Foster TJ, Geoghegan JA, Ganesh VK, Höök M. 2014. Adhesion, invasion and evasion: the many functions of the surface proteins of Staphylococcus aureus. Nat Rev Microbiol 12: 49-62. http://dx.doi.org/10.1038/ nrmicro3161.
19. Murphy E, Lin SL, Nunez L, Andrew L, Fink PS, Dilts DA, Hoiseth SK, Jansen KU, Anderson AS. 2011. Challenges for the evaluation of Staphylococcus aureus protein based vaccines: monitoring antigenic diversity. Hum Vaccin 7(Suppl): 51-59. http://dx.doi.org/10.4161/hv.7.0.14562.
20. Vaudaux PE, François P, Proctor RA, McDevitt D, Foster TJ, Albrecht RM, Lew DP, Wabers H, Cooper SL. 1995. Use of adhesion-defective mutants of Staphylococcus aureus to define the role of specific plasma proteins in promoting bacterial adhesion to canine arteriovenous shunts. Infect Immun 63: 585-590.
21. McDevitt D, Francois P, Vaudaux P, Foster TJ. 1994. Molecular characterization of the clumping factor (fibrinogen receptor) of Staphylococcus aureus. Mol Microbiol 11: 237-248. http://dx.doi.org/10.1111/j.1365-2958.1994.tb00304.x.
22. McDevitt D, Nanavaty T, House-Pompeo K, Bell E, Turner N, McIntire L, Foster T, Höök M. 1997. Characterization of the interaction between the Staphylococcus aureus clumping factor (ClfA) and fibrinogen. Eur J Biochem 247: 416-424. http://dx.doi.org/10.1111/ j.1432-1033.1997.00416.x.
23. McAdow M, Kim HK, Dedent AC, Hendrickx AP, Schneewind O, Missiakas DM. 2011. Preventing Staphylococcus aureus sepsis through the inhibition of its agglutination in blood. PLoS Pathog 7: e1002307. http://dx.doi.org/10.1371/journal.ppat.1002307.
24. Flick MJ, Du X, Prasad JM, Raghu H, Palumbo JS, Smeds E, Höök M, Degen JL. 2013. Genetic elimination of the binding motif on fibrinogen for the S. aureus virulence factor ClfA improves host survival in septicemia. Blood 121: 1783-1794. http://dx.doi.org/10.1182/blood-2012-09-453894.
25. Rothfork JM, Dessus-Babus S, Van Wamel WJ, Cheung AL, Gresham HD. 2003. Fibrinogen depletion attenuates Staphylococcus aureus infection by preventing density-dependent virulence gene upregulation. J Immunol 171: 5389-5395. http://dx.doi.org/10.4049/ jimmunol.171.10.5389.
26. Hair PS, Echague CG, Sholl AM, Watkins JA, Geoghegan JA, Foster TJ, Cunnion KM. 2010. Clumping factor A interaction with complement factor I increases C3b cleavage on the bacterial surface of Staphylococcus aureus and decreases complement-mediated phagocytosis. Infect Immun 78: 1717-1727. http://dx.doi.org/10.1128/IAI.01065-09.
27. Josefsson E, Higgins J, Foster TJ, Tarkowski A. 2008. Fibrinogen binding sites P336 and Y338 of clumping factor A are crucial for Staphylococcus aureus virulence. PLoS One 3: e2206. http://dx.doi.org/10.1371/ journal.pone.0002206.
28. Josefsson E, Hartford O, O’Brien L, Patti JM, Foster T. 2001. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis 184: 1572-1580. http://dx.doi.org/10.1086/324430.
29. Vernachio J, Bayer AS, Le T, Chai YL, Prater B, Schneider A, Ames B, Syribeys P, Robbins J, Patti JM. 2003. Anti-clumping factor A immunoglobulin reduces the duration of methicillin-resistant Staphylococcus aureus bacteremia in an experimental model of infective endocarditis. Antimicrob Agents Chemother 47: 3400-3406. http://dx.doi.org/10.1128/ AAC.47.11.3400-3406.2003.
30. Vernachio JH, Bayer AS, Ames B, Bryant D, Prater BD, Syribeys PJ, Gorovits EL, Patti JM. 2006. Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo. Antimicrob Agents Chemother 50: 511-518. http://dx.doi.org/10.1128/ AAC.50.2.511-518.2006. 50/2/511.
31. DeJonge M, Burchfield D, Bloom B, Duenas M, Walker W, Polak M, Jung E, Millard D, Schelonka R, Eyal F, Morris A, Kapik B, Roberson D, Kesler K, Patti J, Hetherington S. 2007. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr 151: 260-265, 265.e1. http://dx.doi.org/10.1016/j.jpeds.2007.04.060.
32. Capparelli EV, Bloom BT, Kueser TJ, Oelberg DG, Bifano EM, White RD, Schelonka RL, Pearlman SA, Patti J, Hetherington SV. 2005. Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human staphylococcal immune globulin, in low-birth-weight infants. Antimicrob Agents Chemother 49: 4121-4127. http://dx.doi.org/10.1128/AAC.49.10.4121-4127.2005.
33. Bloom B, Schelonka R, Kueser T, Walker W, Jung E, Kaufman D, Kesler K, Roberson D, Patti J, Hetherington S, INH-A21 Phase II Study Team. 2005. Multicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants. Pediatr Infect Dis 24:-858-866. 00006454-200510000-00003.
34. Narita K, Hu DL, Mori F, Wakabayashi K, Iwakura Y, Nakane A. 2010. Role of interleukin-17A in cell-mediated protection against Staphylococcus aureus infection in mice immunized with the fibrinogen-binding domain of clumping factor A. Infect Immun 78: 4234-4242. http:// dx.doi.org/10.1128/IAI.00447-10.
35. Li X, Wang X, Thompson CD, Park S, Park WB, Lee JC. 2016. Preclinical efficacy of clumping factor A in prevention of Staphylococcus aureus infection. mBio 7: e02232-e02215. http://dx.doi.org/10.1128/ mBio.02232-15.
36. Murphy AJ, Macdonald LE, Stevens S, Karow M, Dore AT, Pobursky K, Huang TT, Poueymirou WT, Esau L, Meola M, Mikulka W, Krueger P, Fairhurst J, Valenzuela DM, Papadopoulos N, Yancopoulos GD. 2014. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A 111: 5153-5158. http://dx.doi.org/10.1073/pnas.1324022111.
37. Boulianne GL, Hozumi N, Shulman MJ. 1984. Production of functional chimaeric mouse/human antibody. Nature 312: 643-646. http:// dx.doi.org/10.1038/312643a0.
38. Deivanayagam CC, Wann ER, Chen W, Carson M, Rajashankar KR, Höök M, Narayana SV. 2002. A novel variant of the immunoglobulin fold in surface adhesins of Staphylococcus aureus: crystal structure of the fibrinogen-binding MSCRAMM, clumping factor A. EMBO J 21: 6660-6672. http://dx.doi.org/10.1093/emboj/cdf619.
39. Rauch S, DeDent AC, Kim HK, Bubeck Wardenburg J, Missiakas DM, Schneewind O. 2012. Abscess formation and alpha-hemolysin induced toxicity in a mouse model of Staphylococcus aureus peritoneal infection. Infect Immun 80: 3721-3732. http://dx.doi.org/10.1128/IAI.00442-12.
40. Gresham HD, Lowrance JH, Caver TE, Wilson BS, Cheung AL, Lindberg FP. 2000. Survival of Staphylococcus aureus inside neutrophils contributes to infection. J Immunol 164: 3713-3722. http://dx.doi.org/10.4049/jimmunol.164.7.3713.
41. Tao MH, Morrison SL. 1989. Studies of aglycosylated chimeric mousehuman IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 143: 2595-2601.
42. Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E, Johnson S, Diamond MS, Beatty PR, Harris E. 2010. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 6: e1000790. http://dx.doi.org/10.1371/ journal.ppat.1000790.
43. Riedel S, Carroll KC. 2013. Laboratory detection of sepsis: biomarkers and molecular approaches. Clin Lab Med 33: 413-437. http://dx.doi.org/10.1016/j.cll.2013.03.006.
44. Fowler VG, Allen KB, Moreira ED, Moustafa M, Isgro F, Boucher HW, Corey GR, Carmeli Y, Betts R, Hartzel JS, Chan IS, McNeely TB, Kartsonis NA, Guris D, Onorato MT, Smugar SS, DiNubile MJ, Sobanjo-ter Meulen A. 2013. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA 309: 1368-1378. http://dx.doi.org/10.1001/ jama.2013.3010.
45. Fattom A, Matalon A, Buerkert J, Taylor K, Damaso S, Boutriau D. 2015. Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: phase III randomized study. Hum Vaccin. J Immunother 11: 632-641. http://dx.doi.org/10.4161/hv.34414.
46. Weems JJ, Jr, Steinberg JP, Filler S, Baddley JW, Corey GR, Sampathkumar P, Winston L, John JF, Kubin CJ, Talwani R, Moore T, Patti JM, Hetherington S, Texter M, Wenzel E, Kelley VA, Fowler VG, Jr. 2006. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 50: 2751-2755. http://dx.doi.org/10.1128/AAC.00096-06.
47. Somerville GA, Proctor RA. 2009. At the crossroads of bacterial metabolism and virulence factor synthesis in staphylococci. Microbiol Mol Biol Rev 73: 233-248. http://dx.doi.org/10.1128/MMBR.00005-09.
48. Arya R, Princy SA. 2013. An insight into pleiotropic regulators Agr and Sar: molecular probes paving the new way for antivirulent therapy. Future Microbiol 8: 1339-1353. http://dx.doi.org/10.2217/fmb.13.92.
49. Jenkins A, Diep BA, Mai TT, Vo NH, Warrener P, Suzich J, Stover CK, Sellman BR. 2015. Differential expression and roles of Staphylococcus aureus virulence determinants during colonization and disease. mBio 6: e02272-e02214. http://dx.doi.org/10.1128/mBio.02272-14.
50. Nanra JS, Timofeyeva Y, Buitrago SM, Sellman BR, Dilts DA, Fink P, Nunez L, Hagen M, Matsuka YV, Mininni T, Zhu D, Pavliak V, Green BA, Jansen KU, Anderson AS. 2009. Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design. Vaccine 27: 3276-3280. http://dx.doi.org/10.1016/j.vaccine.2009.01.062.
51. Date SV, Modrusan Z, Lawrence M, Morisaki JH, Toy K, Shah IM, Kim J, Park S, Xu M, Basuino L, Chan L, Zeitschel D, Chambers HF, Tan MW, Brown EJ, Diep BA, Hazenbos WL. 2014. Global gene expression of methicillin-resistant Staphylococcus aureus USA300 during human and mouse infection. J Infect Dis 209: 1542-1550. http://dx.doi.org/10.1093/ infdis/jit668.
52. Malachowa N, Whitney AR, Kobayashi SD, Sturdevant DE, Kennedy AD, Braughton KR, Shabb DW, Diep BA, Chambers HF, Otto M, DeLeo FR. 2011. Global changes in Staphylococcus aureus gene expression in human blood. PLoS One 6: e18617. http://dx.doi.org/10.1371/ journal.pone.0018617.
53. Lattar SM, Noto Llana M, Denoël P, Germain S, Buzzola FR, Lee JC, Sordelli DO. 2014. Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis. Infect Immun 82: 83-91. http://dx.doi.org/10.1128/ IAI.01050-13.
54. Maira-Litrán T, Bentancor LV, Bozkurt-Guzel C, O’Malley JM, Cywes-Bentley C, Pier GB. 2012. Synthesis and evaluation of a conjugate vaccine composed of Staphylococcus aureus poly-N-acetyl-glucosamine and clumping factor A. PLoS One 7: e43813. http://dx.doi.org/10.1371/ journal.pone.0043813.
55. Tuchscherr LP, Buzzola FR, Alvarez LP, Lee JC, Sordelli DO. 2008. Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice. Infect Immun 76: 5738-5744. http:// dx.doi.org/10.1128/IAI.00874-08.
56. Kennedy AD, Bubeck Wardenburg J, Gardner DJ, Long D, Whitney AR, Braughton KR, Schneewind O, DeLeo FR. 2010. Targeting of alphahemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis 202: 1050-1058. http://dx.doi.org/10.1086/656043.
57. Rouha H, Badarau A, Visram ZC, Battles MB, Prinz B, Magyarics Z, Nagy G, Mirkina I, Stulik L, Zerbs M, Jägerhofer M, Maierhofer B, Teubenbacher A, Dolezilkova I, Gross K, Banerjee S, Zauner G, Malafa S, Zmajkovic J, Maier S, Mabry R, Krauland E, Wittrup KD, Gerngross TU, Nagy E. 2015. Five birds, one stone: neutralization of alphahemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody. MAbs 7: 243-254. http:// dx.doi.org/10.4161/19420862.2014.985132.
58. Berube BJ, Bubeck Wardenburg J. 2013. Staphylococcus aureus alphatoxin: nearly a century of intrigue. Toxins (Basel) 5: 1140-1166. http:// dx.doi.org/10.3390/toxins5061140.
59. Powers ME, Wardenburg JB. 2014. Igniting the fire: Staphylococcus au-reus virulence factors in the pathogenesis of sepsis. PLoS Pathog 10: e1003871. http://dx.doi.org/10.1371/journal.ppat.1003871.
60. Bhakdi S, Muhly M, Korom S, Hugo F. 1989. Release of interleukin-1beta associated with potent cytocidal action of staphylococcal alphatoxin on human monocytes. Infect Immun 57: 3512-3519.
61. DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, Bonnell J, Fleming R, Bezabeh B, Dimasi N, Sellman BR, Hilliard J, Guenther CM, Datta V, Zhao W, Gao C, Yu XQ, Suzich JA, Stover CK. 2014. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med 6: 262ra155. http://dx.doi.org/10.1126/scitranslmed.3009655.
62. Rauch S, Gough P, Kim HK, Schneewind O, Missiakas D. 2014. Vaccine protection of leukopenic mice against Staphylococcus aureus bloodstream infection. Infect Immun 82: 4889-4898. http://dx.doi.org/10.1128/ IAI.02328-14.
63. Hawkins J, Kodali S, Matsuka YV, McNeil LK, Mininni T, Scully IL, Vernachio JH, Severina E, Girgenti D, Jansen KU, Anderson AS, Donald RG. 2012. A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure. Clin Vaccine Immunol 19: 1641-1650. http://dx.doi.org/10.1128/CVI.00354-12.
64. Fritz SA, Tiemann KM, Hogan PG, Epplin EK, Rodriguez M, Al-Zubeidi DN, Bubeck Wardenburg J, Hunstad DA. 2013. A serologic correlate of protective immunity against community-onset Staphylococcus aureus infection. Clin Infect Dis 56: 1554-1561. http://dx.doi.org/10.1093/cid/cit123.
65. Sharma-Kuinkel BK, Wu Y, Tabor DE, Mok H, Sellman BR, Jenkins A, Yu L, Jafri HS, Rude TH, Ruffin F, Schell WA, Park LP, Yan Q, Thaden JT, Messina JA, Fowler VG, Jr, Esser MT. 2015. Characterization of alpha-toxin hla gene variants, alpha-toxin expression levels, and levels of antibody to alpha-toxin in hemodialysis and postsurgical patients with Staphylococcus aureus bacteremia. J Clin Microbiol 53: 227-236. http:// dx.doi.org/10.1128/JCM.02023-14.
66. Weisman LE, Thackray HM, Steinhorn RH, Walsh WF, Lassiter HA, Dhanireddy R, Brozanski BS, Palmer KG, Trautman MS, Escobedo M, Meissner HC, Sasidharan P, Fretz J, Kokai-Kun JF, Kramer WG, Fischer GW, Mond JJ. 2011. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics 128: 271-279. http://dx.doi.org/10.1542/peds.2010-3081.
67. Rupp ME, Holley HP, Jr, Lutz J, Dicpinigaitis PV, Woods CW, Levine DP, Veney N, Fowler VG, Jr. 2007. Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 51: 4249-4254. http://dx.doi.org/10.1128/AAC.00570-07.
68. Mathema B, Mediavilla J, Kreiswirth BN. 2008. Sequence analysis of the variable number tandem repeat in Staphylococcus aureus protein A gene: spa typing. Methods Mol Biol 431: 285-305.
69. Kilpatrick KE, Wring SA, Walker DH, Macklin MD, Payne JA, Su JL, Champion BR, Caterson B, McIntyre GD. 1997. Rapid development of affinity matured monoclonal antibodies using RIMMS. Hybridoma 16: 381-389. http://dx.doi.org/10.1089/hyb.1997.16.381.
70. Romero-Steiner S, Libutti D, Pais LB, Dykes J, Anderson P, Whitin JC, Keyserling HL, Carlone GM. 1997. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 4: 415-422.